Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Hua Medicine Advances Diabetes Treatment toward Trial

publication date: Nov 23, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hua Medicine is on track to get its first drug candidate into clinical trials. The molecule is a treatment for type 2 diabetes in-licensed from Roche. Hua filed a request for Clinical Trial Approval in September, and it completed its Site Inspection and Dossier Amendment this week – a process that took only one month instead of the usual three-to-four months. According to Hua, the “well-established drug innovation ecosystem” at Zhangjiang High-Tech Park and its own Collaborative Innovation model of drug R&D were the reasons the drug is advancing so rapidly. More details....

Stock Symbol: (SIX: ROG)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...